Literature DB >> 21240154

Antidepressant induced apathy responsive to dose reduction.

Sreekant Kodela1, Pavan Dontineni Venkata.   

Abstract

Apathy has a significant negative impact on the quality of life. It can be a part of other axis I and axis III disorders such as depression. It has also been reported as a treatment emergent side effect of SSRI drugs. A 48 year old male with diagnosis of personality change due to medical condition and depressive symptoms was started on Sertraline. Although his depressive symptoms, impulse control and his irritability improved significantly he became quite apathetic. This responded positively to a reduction in the dose of sertraline. Since apathy can be a residual symptom of depression it may be a valid consideration to increase the dose of the SSRI. However if apathy was not a significant part of depressive syndrome prior to SSRI treatment then antidepressant treatment emergent apathy needs to be considered and one option is to reduce the dose of the SSRI. Other options appear to be addition of other pharmacological agents such as stimulants, dopamine agonists, acetylcholinesterase inhibitors and NMDA antagonists.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21240154

Source DB:  PubMed          Journal:  Psychopharmacol Bull        ISSN: 0048-5764


  3 in total

1.  Apathy in late-life depression: common, persistent, and disabling.

Authors:  Genevieve S Yuen; Saumya Bhutani; Bryony J Lucas; Faith M Gunning; Bassem AbdelMalak; Joanna K Seirup; Sibel A Klimstra; George S Alexopoulos
Journal:  Am J Geriatr Psychiatry       Date:  2014-06-26       Impact factor: 4.105

2.  Post-stroke apathy and hypersomnia lead to worse outcomes from acute rehabilitation.

Authors:  Ari L Harris; Jessica Elder; Nicholas D Schiff; Jonathan D Victor; Andrew M Goldfine
Journal:  Transl Stroke Res       Date:  2013-10-19       Impact factor: 6.829

3.  Neuroanatomical correlates of apathy in late-life depression and antidepressant treatment response.

Authors:  Genevieve S Yuen; Faith M Gunning; Eric Woods; Sibel A Klimstra; Matthew J Hoptman; George S Alexopoulos
Journal:  J Affect Disord       Date:  2014-05-22       Impact factor: 4.839

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.